Key result
Cytosine and adenine base editors are promising genetic tools for single base substitution, with applications in gene silencing, pathogenic gene correction, and functional genetic screening.
Single base editing using CBEs and ABEs is a promising genetic tool for biomedical research and gene therapy.
Advances base-editing platforms; leaves open clinical cardiovascular translation pending prospective validation.
Cytosine base editors (CBEs) and adenine base editors (ABEs), which are generally composed of an engineered deaminase and a catalytically impaired CRISPR-Cas9 variant, are new favorite tools for single base substitution in cells and organisms. In this review, we summarize the principle of base-editing systems and elaborate on the evolution of different platforms of CBEs and ABEs, including their deaminase, Cas9 variants, and editing outcomes. Moreover, we highlight their applications in mouse and human cells and discuss the challenges and prospects of base editors. The ABE- and CBE systems have been used in gene silencing, pathogenic gene correction, and functional genetic screening. Single base editing is becoming a new promising genetic tool in biomedical research and gene therapy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2019) reported a review. Cytosine base editors (CBEs) and adenine base editors (ABEs) was evaluated. Cytosine and adenine base editors are promising genetic tools for single base substitution, with applications in gene silencing, pathogenic gene correction, and functional genetic screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: